Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver condition linked to excess body fat, high blood lipids, and other metabolic problems. Taiwan green propolis is a natural health product collected by bees from plants, which has shown potential benefits for blood lipids and body fat in laboratory and animal studies. However, its effects in people with MASLD have not been well established in clinical trials. This study is a double-blind, randomized, placebo-controlled trial enrolling up to 60 adults with MASLD at Dalin Tzu Chi Hospital in Taiwan. Eligible participants are randomly assigned in a 1:1 ratio to receive either Taiwan green propolis capsules or matching placebo capsules for 12 weeks. Participants take 2 capsules before breakfast and 2 capsules before dinner each day (4 capsules per day total). Neither participants nor the research team know which capsules are being taken until the study ends. The study measures changes in blood lipids (triglycerides, total cholesterol, LDL-C, and HDL-C), body fat percentage, body weight, waist circumference, liver enzymes, blood sugar levels, inflammatory markers, and health-related quality of life. Liver fat and scarring are assessed by abdominal ultrasound before and after the intervention. Gut microbiota samples are also collected. Assessments are conducted at baseline, at 4 weeks, 8 weeks, 12 weeks (end of intervention), and at follow-up visits 2 weeks and 12 weeks after the intervention ends. The goal of this study is to provide scientific evidence on whether Taiwan green propolis can safely and effectively improve blood lipids, body fat, and metabolic health in people with MASLD, and to explore the relationship between physiological improvements and health behavior changes.
Participants are enrolled at Dalin Tzu Chi Hospital (Dalin Township, Chiayi County, Taiwan). Random allocation is performed using a computer-generated random number sequence with a 1:1 male-to-female ratio, further stratified by physiological life stage (reproductive age, middle age, perimenopausal/menopausal, and elderly). Allocation concealment is achieved using sequentially numbered opaque sealed envelopes, which are opened in order after informed consent is obtained. Intervention arm: Taiwan green propolis capsules (propolis extract), 2 capsules before breakfast and 2 capsules before dinner (4 capsules/day) for 12 consecutive weeks. Capsules may be stored at room temperature. Placebo arm: Capsules containing edible dextrin with vitamin B2 (approximately 0.1 mg/capsule), identical in appearance and administration schedule to the propolis capsules. Both participants and all research personnel involved in assessment and data collection are blinded to group assignment throughout the study period. Assessment schedule: * Baseline: Anthropometrics (height, weight, BMI, waist/hip circumference), skinfold thickness at 7 sites, blood pressure, heart rate, full blood lipid panel, liver enzymes (AST/ALT/GGT), fasting glucose, HbA1c, complete blood count, biochemistry (albumin, BUN, creatinine, uric acid), thyroid function (TSH, T3, free T4), inflammatory cytokines (IL-6, IL-8, IL-1beta), body composition by bioelectrical impedance (InBody), abdominal ultrasound (hepatic steatosis and fibrosis grading), fecal specimen, and all questionnaires. * Weeks 4 and 8: Anthropometrics, skinfold thickness, blood pressure, body composition, blood lipid panel, liver enzymes, fasting glucose, HbA1c, biochemistry, ESAS-R. Inflammatory cytokines added at Week 8. * Week 12 (end of intervention): Full assessment as baseline, except thyroid function; all questionnaires repeated; dietary and activity diary (3 days). * Week 14 (2 weeks post-intervention): Anthropometrics, blood lipid panel, ESAS-R. * Week 24 (12 weeks post-intervention): Full assessment as baseline; all questionnaires; fecal specimen. Questionnaires administered include: General questionnaire, Health Belief Model questionnaire, International Physical Activity Questionnaire (IPAQ Taiwan short form), EQ-5D-5L, Dietary Behavior Scale, and Edmonton Symptom Assessment System-Revised (ESAS-R). Standard care including dietary counseling and appropriate physical activity is provided to all participants throughout the study, regardless of group assignment. Primary statistical analyses will use intention-to-treat principles. Mixed-effects models for repeated measures (MMRM) or analysis of covariance (ANCOVA) will compare changes from baseline between groups for primary and secondary outcomes. Descriptive statistics will be reported for all variables.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
Taiwan green propolis extract capsule taken orally, 4 capsules per day for 12 weeks.
Capsules containing edible dextrin with vitamin B2 (approximately 0.1 mg/capsule), identical in appearance and regimen to the active intervention capsules.
Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Dalin, Taiwan
RECRUITINGChange in Serum Lipid Profile
Change from baseline in fasting serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), measured in mg/dL.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
Change in Skeletal Muscle Mass (InBody)
Change from baseline in skeletal muscle mass measured in kilograms (kg) by InBody bioelectrical impedance analysis.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 24
Change in Fat Mass (InBody)
Change from baseline in total fat mass measured in kilograms (kg) by InBody bioelectrical impedance analysis.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 24
Change in Bone Mass (InBody)
Change from baseline in bone mass measured in kilograms (kg) by InBody bioelectrical impedance analysis.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 24
Change in Waist and Hip Circumference
Change from baseline in waist circumference (cm) and hip circumference (cm) measured by tape measure.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 24
Change in Skinfold Thickness
Change from baseline in skinfold thickness (mm) measured at 7 body sites: chest, axilla, triceps, subscapular, abdomen, suprailiac, and thigh.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 24
Change in Liver Enzymes
Change from baseline in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT), measured in U/L.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
Change in Fasting Plasma Glucose
Change from baseline in fasting plasma glucose concentration, measured in mg/dL.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
Change in Inflammatory Cytokines
Change from baseline in serum interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-1 beta (IL-1β) concentrations.
Time frame: Baseline, Week 8, Week 12, and Week 24
Change in Hepatic Steatosis Grade
Change from baseline in hepatic steatosis grade assessed by abdominal ultrasound (graded as none, mild, moderate, or severe).
Time frame: Baseline and Week 24
Change in Body Weight
Change from baseline in body weight, measured in kilograms (kg).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
Change in Blood Pressure
Change from baseline in systolic blood pressure (mmHg) and diastolic blood pressure (mmHg), measured by sphygmomanometer.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 24
Change in Blood Pressure and Heart Rate
Change from baseline in systolic blood pressure (mmHg), diastolic blood pressure (mmHg), and resting heart rate (bpm).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
Change in EQ-5D-5L Index Score
Change from baseline in EQ-5D-5L utility index score. Scores range from -0.281 to 1.0; higher scores indicate better health-related quality of life.
Time frame: Baseline, Week 12, and Week 24
Change in Physical Activity Level (IPAQ)
Change from baseline in total physical activity measured by the International Physical Activity Questionnaire (IPAQ) Taiwan short form, reported as MET-minutes per week. Higher scores indicate greater physical activity.
Time frame: Baseline and Week 24
Change in Health Belief Model Questionnaire Score
Change from baseline in Health Belief Model questionnaire scores across six subscales: perceived susceptibility, perceived severity, perceived benefits, perceived barriers, behavioral intention, and self-efficacy. Each item rated on a 5-point Likert scale (1=strongly disagree to 5=strongly agree). Higher scores indicate stronger health beliefs.
Time frame: Baseline and Week 24
Change in Dietary Behavior
Change from baseline in dietary behavior questionnaire score assessing eating habits and food intake patterns.
Time frame: Baseline and Week 24
Symptom Burden (ESAS-R)
Symptom burden assessed by the Edmonton Symptom Assessment System-Revised (ESAS-R). Each symptom rated 0-10; higher scores indicate greater symptom severity.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
Change in Gut Microbiota Composition
Change from baseline in gut microbiota composition and diversity assessed from fecal specimens collected in sterile containers and stored at -20°C.
Time frame: Baseline and Week 24
Incidence of Adverse Events
Incidence, type, and severity of adverse events and clinically significant abnormal laboratory findings throughout the study period.
Time frame: Throughout study, up to Week 24
Change in Body Mass Index (BMI)
Change from baseline in BMI, calculated as weight in kilograms divided by height in meters squared (kg/m\^2).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
Change in Glycated Hemoglobin (HbA1c)
Change from baseline in glycated hemoglobin (HbA1c), measured as a percentage (%).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
Change in Hepatic Fibrosis Severity
Change from baseline in hepatic fibrosis severity assessed by abdominal ultrasound.
Time frame: Baseline and Week 24
Change in Resting Heart Rate
Change from baseline in resting heart rate, measured in beats per minute (bpm).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
Change in EQ Visual Analogue Scale (EQ-VAS) Score
Change from baseline in EQ-VAS score. Scores range from 0 to 100; higher scores indicate better self-rated health.
Time frame: Baseline, Week 12, and Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.